Le Lézard2d
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Contineum Therapeutics, Inc. (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology ...
The University of Chicago Chronicle5d
Thirty-one UChicago faculty members receive named, distinguished service professorships in 2025
Thirty-one members of the University of Chicago faculty have received distinguished service professorships or named ...
Medindia1d
Ouro Medicines Launches to Define the Future of Treatment for People with Immune-Mediated Diseases
Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, ...
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
Srinivas RaoM.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D.
Pharmabiz2d
Illumina advances NovaSeq X Series, delivering single-flow-cell system, software upgrade, and new kits to enable multiomic applications
Illumina advances NovaSeq X Series, delivering single-flow-cell system, software upgrade, and new kits to enable multiomic applications: San Diego Thursday, January 9, 2025, 14:00 ...
ETF Daily News6d
Alto Neuroscience, Inc. (NYSE:ANRO) Stake Raised by Geode Capital Management LLC
Geode Capital Management LLC grew its holdings in shares of Alto Neuroscience, Inc. (NYSE:ANRO – Free Report) by 148.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 469,988 ...
CES 2025 Hat Trick: FRENZ Brainband Secures 3rd CES Innovation Awards, Launching Focus Feature for Daily Life
The Consumer Technology Association (CTA) honors Earable® Neuroscience with a CES 2025 Innovation Awards® in Digital Health, ...
Hosted on MSN2d
All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy
Alto Neuroscience, Inc. (ANRO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
Stockhouse5d
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 6, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto ...
Yahoo Finance5d
Reunion Neuroscience Announces Program Updates and Highlights Anticipated 2025 Milestones
MORRISTOWN, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health ...
Investing5d
Firefly Neuroscience announces board and CEO changes
Firefly Neuroscience, Inc. (AIFF), a prepackaged software company trading on The Nasdaq Capital Market, has reported significant leadership changes amid challenging market conditions. According to ...
Investing4d
Firefly Neuroscience announces board and CEO changes
Firefly Neuroscience, Inc. (AIFF), a prepackaged software company trading on The Nasdaq Capital Market, has reported significant leadership changes amid challenging market conditions. According to ...